慢性肝病成人甲型肝炎和乙型肝炎疫苗接种覆盖率
研究利用2014年和2015年美国国民健康访谈调查数据,评估自报慢性肝病成人甲肝和乙肝疫苗接种覆盖率。慢性肝病成人中19.4%和11.5%分别报告接种至少1剂和至少2剂甲肝疫苗,35.7%和29.1%分别报告接种至少1剂和至少3剂乙肝疫苗;在就诊≥10次的慢性肝病成人中,仅13.8%和35.3%分别接种至少2剂甲肝疫苗和至少3剂乙肝疫苗。作者认为慢性肝病成人疫苗接种不理想,存在错失接种机会,提供者应遵循推荐为慢性肝病人群接种。
要点
- 慢性肝病成人甲肝疫苗≥1剂和≥2剂覆盖率分别为19.4%和11.5%。
- 慢性肝病成人乙肝疫苗≥1剂和≥3剂覆盖率分别为35.7%和29.1%。
- 就诊≥10次的慢性肝病成人中仅13.8%接种≥2剂甲肝疫苗、35.3%接种≥3剂乙肝疫苗。
核心结论
- 慢性肝病成人甲肝和乙肝疫苗接种不理想,存在错失接种机会,提供者应遵循推荐为慢性肝病人群接种以提高接种率。
研究设计与样本
- 研究使用2014年和2015年美国国民健康访谈调查(NHIS)数据,该调查为美国非机构化平民人群的全国代表性面对面访谈调查。
- 研究评估自报慢性或长期肝脏疾病成人中自报甲肝疫苗(≥1剂和≥2剂)和乙肝疫苗(≥1剂和≥3剂)接种覆盖率。
- 研究使用多变量逻辑回归识别与慢性肝病成人甲肝和乙肝疫苗接种独立相关的因素。
主要发现
- 慢性肝病成人中19.4%报告接种≥1剂甲肝疫苗、11.5%报告接种≥2剂,无慢性肝病成人中分别为14.7%和9.1%(≥1剂比较p < .05)。
- 慢性肝病成人中35.7%报告接种≥1剂乙肝疫苗、29.1%报告接种≥3剂,无慢性肝病成人中分别为30.2%和24.7%(≥1剂比较p < .05)。
- 在慢性肝病成人中,年龄、教育程度、地理区域和国际旅行与接种≥2剂甲肝疫苗相关。
- 在慢性肝病成人中,年龄、教育程度和过去12个月内接种流感疫苗与接种≥3剂乙肝疫苗相关。
- 在就诊≥10次的慢性肝病成人中,仅13.8%接种≥2剂甲肝疫苗、35.3%接种≥3剂乙肝疫苗。
关键数值与推荐
- 免疫实践咨询委员会(ACIP)推荐慢性肝病患者接种甲肝疫苗和乙肝疫苗。
临床怎么用
- 提供者应遵循推荐为慢性肝病患者接种疫苗,以提高该人群的接种率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infection with hepatitis A and hepatitis B virus can increase the risk of morbidity and mortality in persons with chronic liver disease (CLD). The Advisory Committee on Immunization Practices recommends hepatitis A (HepA) and hepatitis B (HepB) vaccination for persons with CLD. METHODS: Data from the 2014 and 2015 National Health Interview Surveys (NHIS), nationally representative, in-person interview surveys of the non-institutionalized US civilian population, were used to assess self-reported HepA (≥1 and ≥2 doses) and HepB vaccination (≥1 and ≥3 doses) coverage among adults who reported a chronic or long-term liver condition. Multivariable logistic regression was used to identify factors independently associated with HepA and HepB vaccination among adults with CLD. RESULTS: Overall, 19.4% and 11.5% of adults aged ≥ 18 years with CLD reported receiving ≥1 dose and ≥2 doses of HepA vaccine, respectively, compared with 14.7% and 9.1% of adults without CLD (p < .05 comparing those with and without CLD, ≥1dose). Age, education, geographic region, and international travel were associated with receipt of ≥2 doses HepA vaccine among adults with CLD. Overall, 35.7% and 29.1% of adults with CLD reported receiving ≥1 dose and ≥3 doses of HepB vaccine, respectively, compared with 30.2% and 24.7% of adults without CLD (p < .05 comparing those with and without CLD, ≥1 dose). Age, education, and receipt of influenza vaccination in the past 12 months were associated with receipt of ≥3 doses HepB vaccine among adults with CLD. Among adults with CLD and ≥10 provider visits, only 13.8% and 35.3% had received ≥2 doses HepA and ≥3 doses HepB vaccine, respectively. CONCLUSIONS: HepA and HepB vaccination among adults with CLD is suboptimal and missed opportunities to vaccinate occurred. Providers should adhere to recommendations to vaccinate persons with CLD to increase vaccination among this population.
引用
- Yue X, Black CL, O'Halloran A, et al. Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. Vaccine. 2018. PMID: 29395521. doi:10.1016/j.vaccine.2018.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。